Answer
The oral solution is licensed for certain nucleoside-naive children and adolescents aged 2 to under 18 years with compensated chronic hepatitis B. A paediatric specialist determines suitability.
Sources for this answer
- Baraclude 0.05 mg/ml oral solution — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.